Horizon Therapeutics Public (HZNP) Stock Forecast, Price & News

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Horizon Therapeutics Public in the last year. There are currently 8 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" HZNP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HZNP, but not buy additional shares or sell existing shares.
View HZNP analyst ratings or view top-rated stocks.

11 analysts have issued 1 year price objectives for Horizon Therapeutics Public's stock. Their HZNP share price forecasts range from $71.00 to $144.00. On average, they expect the company's stock price to reach $111.42 in the next year. This suggests a possible upside of 11.4% from the stock's current price.
View analysts price targets for HZNP or view top-rated stocks among Wall Street analysts.

Horizon Therapeutics Public's stock was trading at $113.80 at the beginning of the year. Since then, HZNP stock has decreased by 12.1% and is now trading at $100.03.
View the best growth stocks for 2023 here.

Horizon Therapeutics Public saw a increase in short interest in May. As of May 15th, there was short interest totaling 6,950,000 shares, an increase of 5.8% from the April 30th total of 6,570,000 shares. Based on an average daily trading volume, of 2,290,000 shares, the short-interest ratio is currently 3.0 days.
View Horizon Therapeutics Public's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023.
View our HZNP earnings forecast.

Horizon Therapeutics Public Limited (NASDAQ:HZNP) announced its quarterly earnings data on Wednesday, May, 3rd. The biopharmaceutical company reported $0.83 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.17 by $0.34. The biopharmaceutical company had revenue of $832.10 million for the quarter, compared to analyst estimates of $897.06 million. Horizon Therapeutics Public had a trailing twelve-month return on equity of 20.31% and a net margin of 10.40%. The business's revenue for the quarter was down 6.0% compared to the same quarter last year. During the same period last year, the firm earned $1.34 EPS.

ETFs with the largest weight of Horizon Therapeutics Public (NASDAQ:HZNP) stock in their portfolio include First Trust Merger Arbitrage ETF (MARB), AltShares Merger Arbitrage ETF (ARB), IQ Merger Arbitrage ETF (MNA), Pinnacle Focused Opportunities ETF (FCUS), AltShares Event-Driven ET (EVNT), Invesco Dynamic Pharmaceuticals ETF (PJP), Subversive Mental Health ETF (SANE) and VictoryShares Nasdaq Next 50 ETF (QQQN).

70 employees have rated Horizon Therapeutics Public Chief Executive Officer Timothy Walbert on Glassdoor.com. Timothy Walbert has an approval rating of 73% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Horizon Therapeutics Public investors own include Alibaba Group (BABA), NVIDIA (NVDA), OPKO Health (OPK), Advanced Micro Devices (AMD), Netflix (NFLX), Gilead Sciences (GILD), Tesla (TSLA), AbbVie (ABBV), Micron Technology (MU) and PayPal (PYPL).

Horizon Therapeutics Public trades on the NASDAQ under the ticker symbol "HZNP."

Horizon Therapeutics Public's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.53%), JPMorgan Chase & Co. (2.40%), Farallon Capital Management LLC (2.37%), State Street Corp (2.24%), Renaissance Technologies LLC (1.47%) and Geode Capital Management LLC (1.39%). Insiders that own company stock include Aaron Cox, Andy Pasternak, Barry Moze, Brian K Beeler, Daniel A Camardo, Elizabeth HZ Thompson, Geoffrey M Curtis, Irina Konstantinovsky, Jeff Kent, Jeffrey W Sherman, Jeffrey W Sherman, Michael A Desjardin, Michael G Grey, Miles W Mchugh, Paul W Hoelscher, Paul W Hoelscher, Sean M Clayton, Timothy P Walbert, Timothy P Walbert, Vikram Karnani and William F Daniel.
View institutional ownership trends.

Shares of HZNP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of HZNP stock can currently be purchased for approximately $100.03.

Horizon Therapeutics Public (NASDAQ:HZNP) has a market capitalization of $22.87 billion and generates $3.63 billion in revenue each year. The biopharmaceutical company earns $521.48 million in net income (profit) each year or $1.59 on an earnings per share basis.

The company employs 2,115 workers across the globe.

Horizon Therapeutics Public's mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE 1ST FLOOR, Dublin L2, D04 C5Y6. The official website for the company is www.horizontherapeutics.com. The biopharmaceutical company can be reached via phone at (531) 772-2100, via email at investor-relations@horizontherapeutics.com, or via fax at 224-383-3001.